Back to search

Netherlands· NL-4dcfa890097b

Teriparatide Aristo 20 microgram/ 80 microliter oplossing voor injectie in voorgevulde pen

A teriparatide product containing teriparatideacetaat, registered in Netherlands by Aristo Pharma GmbH. The same ATC class is registered in 18 of our 19 countries.

ATC H05AA02

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedTeriparatide Aristo 20 microgram/ 80 …ATCH05AA02REGISTER NO.NL-4dcfa890097bPACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Teriparatide is registered in 18 of 19 countries.

Countries holding a registration under ATC H05AA02 (teriparatide), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 10 of them publish a price we can compare per daily dose

Teriparatide · ATC H05AA02

18 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of teriparatide costs, country by country.

Normalised to the WHO defined daily dose (20 mcg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Teriparatide · price per daily dose (20 mcg)

USD · FX 28 Sept 2026

  • CH Switzerland$26.86
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
TERIPARATIDEACETAAT
Manufacturer
Aristo Pharma GmbH
Country
Netherlands (NL)
ATC code
H05AA02
ATC class
Teriparatide
Defined daily dose
20 mcg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    124520

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

6 interactions on record for teriparatide.

Graded by severity as the source publishes them — 4 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Teriparatide · interactions on record

6 records

  • 4 moderate
  • 2 minor

Most severe, free to view

  • DigitoxinC01AA04moderate
  • DigoxinC01AA05moderate
  • CalcipotriolD05AX02moderate
  • CalcitriolD05AX03moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Teriparatide in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All teriparatide products

Authorised across Europe · EMA

The same active substance is authorised in 19 EEA countries. Names it is sold under:

  • Austria · Teriparatid +pharma, Teriparatid Cipla
  • Bulgaria · Osteoteri
  • Cyprus · Bonamens
  • Germany · Osteoteri, Teriparatid Ambio Pharma
  • Denmark · Tetridar
  • Spain · Duratil, Osdy
  • France · Teriparatide Ambio Pharma, Teriparatide Biogaran
  • United Kingdom (Northern Ireland) · Movymia, Teriparatide Ambio Pharma
  • Greece · Bonamens, Osteorel
  • Croatia · Teriparatid Pliva
  • Hungary · Osteoteri, Teriparatid Teva
  • Ireland · Teriparatide Cipla, Tetridar
  • Iceland · Forsteo, Kauliv
  • Italy · Oseffyl, Patride
  • Liechtenstein · Forsteo, Kauliv
  • Norway · Forsteo, Kauliv
  • Poland · Osteoteri
  • Portugal · Teriparatida Ratiopharm
  • Sweden · Teriparatide Ambio Pharma, Teriparatide Teva

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d84be4a1-4687-4cfe-8e8a-0adb6abad3ef
GET /v1/drugs/d84be4a1-4687-4cfe-8e8a-0adb6abad3ef?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor injectie",
  "route": "Subcutaan gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h124520_smpc.pdf",
  "strength": null,
  "atc_label": "Teriparatide",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg124520",
  "excipients": [
    "AZIJNZUUR (E 260), GECONCENTREERD",
    "MANNITOL (D-) (E 421)",
    "METACRESOL",
    "NATRIUMACETAAT 0-WATER (E 262)",
    "NATRIUMHYDROXIDE (E 524)",
    "WATER VOOR INJECTIE",
    "ZOUTZUUR (E 507)"
  ],
  "substances": [
    "TERIPARATIDEACETAAT"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h124520.pdf",
  "authorised_at": "2020/09/14",
  "procedure_number": "DE/H/6143/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "124520",
  "additional_monitoring": "N"
}

See everything about teriparatide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.